{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-015880","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2025-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.584444+00:00","generated_at":"2026-05-23T04:43:25.920525+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"medium","headline":"Gyre Therapeutics posts updated corporate presentation; no material financial disclosures","bullets":["Presentation titled 'Developing Anti-Fibrotic Therapeutics for Chronic Organ Diseases' made available on company website.","No new financial data, guidance, or clinical trial results disclosed in the filing or exhibit.","Presentation is furnished under Regulation FD; not deemed filed for SEC purposes.","Company continues to focus on fibrotic disease therapies; no changes to strategy announced."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-015880","json":"https://secwatch.observer/filing/0001140361-25-015880.json","markdown":"https://secwatch.observer/filing/0001140361-25-015880.md","text":"https://secwatch.observer/filing/0001140361-25-015880.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125015880/0001140361-25-015880-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125015880/ef20048044_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T04:43:25.920525+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}